CHICAGO - More bad news for CytRx (CYTR) at the American Society of Clinical Oncology annual meeting.

Results from the phase III study of CytRx's aldoxorubicin in front-line sarcoma patients were presented on Friday. The company had previously acknowledged aldoxorubicin's failure to significantly prolong progression-free survival, the study's primary endpoint. 

But what about survival? Maybe aldoxorubicin is helping sarcoma patients live longer? 

No, it is not. 

Read More Trending Articles:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

General Electric Slips as Cowen Suggests Culp Needs to Take Action

General Electric Slips as Cowen Suggests Culp Needs to Take Action

Investors Face Growing Opportunities and Challenges in Cannabis

Investors Face Growing Opportunities and Challenges in Cannabis

J.C. Penney Shares Have Plunged 64% Since Quant Ratings Downgrade

J.C. Penney Shares Have Plunged 64% Since Quant Ratings Downgrade

The 'Fear of Missing Out' Is Missing

The 'Fear of Missing Out' Is Missing

Bye, Bye, Bye Sears: The Week Ahead

Bye, Bye, Bye Sears: The Week Ahead